GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: example 17 [WO2015008073] | HTL-14242 | HTL0014242 | HTL14242 | TMP301
Compound class:
Synthetic organic
Comment: TMP-301 (formerly HTL0014242) is a selective, and orally bioavailable mGluR5 negative allosteric modulator (NAM) [1].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| No information available. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT06648668 | A Study to Investigate the Interaction Between TMP-301 and Cocaine. | Phase 1 Interventional | Tempero Bio, Inc. | ||
| NCT06648655 | A Study to Investigate the Safety and Efficacy of TMP-301 Compared to Placebo in Adult Patients With Alcohol Use Disorder | Phase 2 Interventional | Tempero Bio, Inc. | ||
| NCT06025396 | Multiple Ascending Dose Study of TMP-301 in Healthy Subjects | Phase 1 Interventional | Tempero Bio, Inc. | ||
| NCT03785054 | Phase 1, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of mGlu5 NAM HTL0014242 | Phase 1 Interventional | Nxera Pharma UK Limited | This was the first in humans study for HTL0014242/TMP-301. | |